Is it safe to discontinue long-term trastuzumab containing therapy after radiological complete response (rCR) in metastatic HER-2 positive breast cancer (MBC)?

Calamac, Marina; Stanic, Nemanja S; Djurmez, Ognjen; Dimitrijevic, M; Vukosavljevic, JG; Serovic, Kristina; Oblakovic-Babic, Jelena S; Minic, Ivana Z; Bozovic-Spasojevic, Ivana M

Results

eNauka > Results > Is it safe to discontinue long-term trastuzumab containing therapy after radiological complete response (rCR) in metastatic HER-2 positive breast cancer (MBC)?

Title:	Is it safe to discontinue long-term trastuzumab containing therapy after radiological complete response (rCR) in metastatic HER-2 positive breast cancer (MBC)?
Authors:	Calamac, Marina; Stanic, Nemanja S; Djurmez, Ognjen; Dimitrijevic, M; Vukosavljevic, JG; Serovic, Kristina; Oblakovic-Babic, Jelena S; Minic, Ivana Z; Bozovic-Spasojevic, Ivana M
Issue Date:	2023
Publication:	BREAST
ISSN:	0960-9776 Breast Search Idenfier
Type:	Conference Paper
Collation:	vol. 68 str. S130-S131
WoS-ID:	001037996400290
URI:	https://enauka.gov.rs/handle/123456789/808004
Metadata source:	(Preuzeto iz Nasi u WoS)
M-category:	Mp. category will be shown later

Find the DOI

Finding a DOI in CrossRef based on publication meta-data. The DOI (and metadata) with the similar data match will be displayed. ATTENTION - it doesn't have to be that publication.

Google Scholar^TM